CA
ATYR

Clearstead Advisors’s aTyr Pharma ATYR Stock Holding History

Clearstead Advisors’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$515 Buy
+861
New +$562 ﹤0.01% 2912

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clearstead Advisors's ATYR Position: Q2 2026 in Review

Clearstead Advisors opened a new position in aTyr Pharma (ATYR) in Q2 2026: 861 shares worth $515. The stake represents ﹤0.01% of the portfolio and ranks #2912 among its holdings.

90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Clearstead Advisors held 861 shares of aTyr Pharma worth $515 as of Q2 2026.
  • aTyr Pharma was a new Clearstead Advisors position in Q2 2026.
  • aTyr Pharma made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #2912 holding.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.